Phio Pharmaceuticals Corp (PHIO)

[jondoeuk]

From this: ''Phio’s lead candidate, RXI-762, is pursuing immuno-oncology indications in collaboration with Center for Cancer Immune Therapy (CCIT) and Iovance Biotherapeutics. Development efforts are centered on reducing the immune checkpoints that appear on the surface of tumor infiltrating lymphocytes (TILs) in an approach that can be layered on to current manufacturing processes. In-vitro efficacy and safety data is being generated and regulatory work is underway in order to prepare the investigational new drug (IND) application. Phio is currently developing the data set needed to satisfy the requirements for the IND and we expect a further update on progress in a few months.''

https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2019/PHIO-Two-Compounds-Entering-Clinic-in-2020-article/default.aspx